PPP2CA and prostate carcinoma: PPP2CA mutation and deep deletion events occur in 0.4–1.4% of patients with prostate cancer (Tables S1–S3), further highlighting the diversity of genetic aberrations in AKT regulators that could promote oncogenic PI3K signaling.